Skip to content

← All news

Markets

Piper Sandler reiterates Kymera Therapeutics stock rating at $140

1 source ·1 article ·Sep 23, 13:30 UTC Kymera Therapeutics

Covered by 1 outlet

All coverage · 1 article

Investing.com UK ·Sep 23, 13:30 UTC

Piper Sandler reiterates Kymera Therapeutics stock rating at $140